Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

Summary: Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of c...

Full description

Bibliographic Details
Main Authors: David R. Martinez, Alexandra Schäfer, Sarah R. Leist, Dapeng Li, Kendra Gully, Boyd Yount, Joy Y. Feng, Elaine Bunyan, Danielle P. Porter, Tomas Cihlar, Stephanie A. Montgomery, Barton F. Haynes, Ralph S. Baric, Michel C. Nussenzweig, Timothy P. Sheahan
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:Cell Reports
Subjects:
SARS-CoV-2
B.1.351
variants
remdesivir
RDV
monoclonal antibodies
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124721008676

Internet

http://www.sciencedirect.com/science/article/pii/S2211124721008676

Similar Items